ROVEN Strategy | Commercialization & Adoption
The strategic second opinion for MedTech and Healthcare AI. We diagnose stalled commercial pipelines for founders, and conduct commercial due diligence for the private equity investors backing them.
01. The Problem
You cleared FDA. Clinicians love the demo. The pipeline is full of verbal yeses. Nothing converts. The board is asking why, and the honest answer is you don’t know yet.
02. The Offer
For Founders & Operators
A full-field diagnosis of your stalled pipeline: where deals die, why, and a prioritized fix plan.
What’s included
For PE Investors & Boards
The strategic second opinion before your next major capital commitment.
Independent vetting of GTM viability, market friction, and clinical adoption risks before you sign a term sheet, acquire a target, or greenlight a major market expansion.
What’s included
04. Who this is for
Series A or B MedTech or imaging AI.
Post-FDA clearance, 12 to 30 months into commercialization.
Missing your number and tired of guessing why.
Private Equity & VC Partners needing ground-truth commercial due diligence on a MedTech asset before committing capital.
05. Why Me
15+ years clinical-to-commercial. I started as a radiological technologist and cardiac scrub tech in ORs, cath labs, and trauma centers.
Then I ranked #1 of 204 nationally selling capital imaging for a Fortune 500 healthcare company, and went on to lead commercial teams at five MedTech and healthcare AI startups.
I’ve watched deals stall from both sides of the wall: the clinicians who won’t adopt and the sales orgs that can’t see why. That’s the stall I find.
Because I’ve sat on both sides of the wall, as a clinician and a commercial leader, I see the blind spots that boardroom strategies miss. That is why I founded ROVEN Strategy: to give leaders an independent, strategic second opinion before they commit capital, time, and reputation.
Awards
Experience
Advisory & Mentorship
Renée Gutierrez
Founder & Principal